A California jury sided with J&J Nov. 16 in the first trial over whether alleged asbestos in the firm's talcum powders caused plaintiff's mesothelioma. The verdict could help check what threatens to be a new field of litigation against J&J for alleged talc dangers, and the firm also is gaining momentum in its defense against ovarian cancer claims.
Johnson & Johnson and its talc supplier say Johnson's Baby Powder and Shower to Shower offerings are and always have been clean of asbestos, and the evidence convinced a California jury Nov. 16 in the first US trial examining alleged links between J&J powders and mesothelioma.
According to J&J, plaintiff Tina Herford's assertion that asbestos-contaminated talc in J&J products caused her mesothelioma is a "baseless theory,"...
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
